Home » SAMARITAN ENTERS INTO EXCLUSIVE SUPPLY AGREEMENT WITH NORBROOK FOR ORAL ENTRY INHIBITOR HIV DRUG
SAMARITAN ENTERS INTO EXCLUSIVE SUPPLY AGREEMENT WITH NORBROOK FOR ORAL ENTRY INHIBITOR HIV DRUG
September 28, 2005
Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has entered into an exclusive five-year supply agreement with Norbrook Laboratories, S.R.O. to supply raw formulation material to Samaritan's collaborative manufacturing partner Pharmaplaz, Ireland for SP-01A, Samaritan's lead HIV drug, upon approval from a regulatory authority. Norbrook Laboratories Ltd., operating through its Czech subsidiary, P.F. Services, Czech Republic, is presently the only supplier with an FDA Drug Master File ("DMF") for the raw formulation material of SP-01A.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050927005915&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct